Persistent Launches AI-Powered Generative Molecules and Virtual Screening Solution Powered by NVIDIA

Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework

Mar. 17, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

Persistent Systems, a global Digital Engineering and Enterprise Modernization leader, has announced a collaboration with NVIDIA to accelerate the development and deployment of AI-powered solutions for the Healthcare and Life Sciences (HLS) industry. The collaboration will help HLS organizations advance computational drug discovery and improve research outcomes using Generative AI and advanced analytics.

Why it matters

HLS organizations are under increasing pressure to drive innovation while operating in highly complex, regulated and data-intensive environments. By combining Persistent's deep domain and engineering expertise with the full-stack NVIDIA AI platform, Life Sciences enterprises can move from AI experimentation to real-world production deployments in mission-critical environments, accelerating the development of new therapies.

The details

As part of this collaboration, Persistent will build and deploy production-grade Agentic AI applications for computational drug discovery using NVIDIA NeMo. Specifically, Persistent has created a Generative Molecules and Virtual Screening (GenMoIVS) solution, powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. GenMolVS will deliver AI-driven molecular simulations that model the physical and chemical properties of molecules using large domain-specific models and create intelligent agents to streamline real-time drug discovery workflows.

  • The collaboration was announced on March 17, 2026.

The players

Persistent Systems

A global Digital Engineering and Enterprise Modernization leader.

NVIDIA

A technology company that specializes in the design and manufacture of graphics processing units (GPUs) and other related technologies.

Ganesh Nathella

Executive Vice President and General Manager - HLS Business at Persistent.

John Fanelli

Vice President - Enterprise Software at NVIDIA.

Got photos? Submit your photos here. ›

What they’re saying

“Healthcare and Life Sciences organizations need to discover new therapies faster, but traditional R&D is too slow and labor-intensive. By combining our GenMolVS solution with NVIDIA full-stack AI platform, we enable BioPharma clients to use generative molecules and virtual screening in production so they can move from months-long experiments to AI-driven discovery in days, using simulation-led intelligence to guide real-world experimentation without compromising on scientific rigor or compliance.”

— Ganesh Nathella, Executive Vice President and General Manager - HLS Business, Persistent

“To meet the urgent global demand for new therapies, the healthcare and life sciences industry is rapidly moving toward AI-driven computational research and discovery. By leveraging the full-stack NVIDIA AI platform, Persistent is empowering biopharma companies with production-grade agentic systems for molecular simulation and virtual screening.”

— John Fanelli, Vice President - Enterprise Software, NVIDIA

What’s next

Persistent is planning to use NVIDIA Nemotron open models for further enhancement of its GenMolVS solution. Furthermore, to deploy production-grade AI applications, Persistent will use NVIDIA accelerated computes, servers, NVIDIA AI Enterprise and NVIDIA NIM microservices.

The takeaway

By combining Persistent's deep domain and engineering expertise with the full-stack NVIDIA AI platform, Life Sciences enterprises can move from AI experimentation to real-world production deployments in mission-critical environments, accelerating the development of new therapies and improving research outcomes.